Holen Sie sich die Stockscreener-App
0.9166
11.01%
-0.1134
Handel nachbörslich:
.92
0.0034
+0.37%
Finanzdaten der Lyell Immunopharma Inc-Aktie (LYEL)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
| Enddatum des Zeitraums | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
| Revenues |
76.92%
0.003
|
0.013 | 0.025 | 0.027 | 0.065 |
Operating Expenses
|
6.62%
55.58
|
59.52 | 59.06 | 65.93 | 62.62 |
| Benefits Costs and Expenses |
-
|
- | - | - | - |
| Costs And Expenses |
6.62%
55.58
|
59.52 | 59.06 | 65.93 | 62.62 |
| Operating Income/Loss |
6.61%
-55.58
|
-59.51 | -59.04 | -65.91 | -62.56 |
| Nonoperating Income/Loss |
177.41%
-5.092
|
6.578 | 8.186 | 2.015 | -4.403 |
| Income/Loss From Continuing Operations Before Tax |
76.92%
0.003
|
0.013 | 0.025 | 0.027 | 0.065 |
| Income/Loss From Continuing Operations After Tax |
14.62%
-60.67
|
-52.93 | -50.85 | -63.89 | -66.96 |
|
Net Income/Loss
|
14.62%
-60.67
|
-52.93 | -50.85 | -63.89 | -66.96 |
| Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
| Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
| Basic Average Shares |
41,856%
254.25
|
0.606 | 251.32 | 250.20 | 249.59 |
| Diluted Average Shares |
41,856%
254.25
|
0.606 | 251.32 | 250.20 | 249.59 |
| Basic Earnings Per Share |
20.00%
-0.24
|
-0.20 | -0.20 | -0.26 | -0.27 |
| Diluted Earnings Per Share |
20.00%
-0.24
|
-0.20 | -0.20 | -0.26 | -0.27 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
0.93%
3.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):